Events

Our powerful resins, Strep-Tactin®XT 4Flow® and Strep-Tactin®XT 4Flow® high capacity, replace Strep-Tactin®XT Superflow® as well as Strep-Tactin®XT Superflow® high capacity as of July 1st, 2021. In comparison to Strep-Tactin®XT Superflow® resins, Strep-Tactin®XT 4Flow® resins have improved and enhanced properties and are, therefore, our Strep-Tactin®XT resins for the future.

Strep-Tactin®XT 4Flow® and the high capacity variant are perfectly suitable for efficient protein purification independent from the protein class, including challenging proteins, low abundant proteins and especially large proteins. Furthermore, the broad pH stability enhanced the compatibility with different buffer compositions.

The new structure organizes IBA Lifesciences’ core business operations around two strategic departments: Protein Production & Assays and Cell Selection & Expansion. These product lines are united by IBAs’ proprietary and versatile platform, the Strep-tag® technology.

As part of this process, IBA will discontinue the production of custom oligonucleotides. All employees of the Custom Oligo & Predefined DNA/RNA department will be merged into the remaining two departments. As a result, this will strengthen the production as well as research and development of the protein production and cell selection tools.
The Custom Oligos & Predefined DNA/RNA department has served IBAs’ customers with specialized nucleic acid products and oligonucleotides since 1998. The company is extremely proud of all the accomplishments of the department in those years. Existing orders will be honored and IBA is working hard to ensure a timely delivery of the products.

Mike Rothe, IBA’s CEO said, “Focusing on our core technology will help us expand into promising new product areas, such as the field of exosome isolation. This is a key step in our strategic, long-term plan to better meet the demands of our globally expanding businesses, especially in Asia. The current re-allocation of resources will enable us to respond very quickly to the increasing demand of protein production and cell selection tools. This will result in major changes in efficiencies and position us well for future success.”

The company will begin to implement the restructuring immediately, and the reorganization is expected to be completed by September 2020.

About IBA Lifesciences
Founded in 1996, IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. IBA’s portfolio includes tools for cell selection and expansion as well as protein production and assays.

Contact details
Anna Färger
Director Marketing / PR
IBA GmbH
Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany
+49 (0)551 50672-0
info@iba-lifesciences.com
www.iba-lifesciences.com

IBA GmbH is nominated for the Lower Saxony Innovation Prize 2019
The project: Zellclean

Zellclean stands for the successful combination of medical laboratory equipment (FABian®), biological separation process based on the Fab-TACS® technology (Traceless Affinity Cell Selection) developed by IBA GmbH for reversible immunochromatography of cells and innovative research with regional cooperation partners in Lower Saxony. The result of Zellclean is the design, development and manufacture of a disposable cell separation unit for the FABian®, with which specific cells can be automatically isolated from human whole blood samples and used for research, therapy and diagnostics.

You can find the nomination video here.